biostudies-literatureLowenthal EDNational Institute of Allergy and Infectious DiseasesEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNICHD NIH HHSNIAID NIH HHSNational Institute of Mental HealthNational Institutes of HealthInternational Maternal Pediatric Adolescent AIDS Clinical Trials Networke222-e232https://www.ebi.ac.uk/biostudies/studies/S-EPMC11061207biostudies-literatureUnknown11(4)<h4>Background</h4>Long-acting injectable cabotegravir and rilpivirine have demonstrated safety, acceptability, and efficacy in adults living with HIV-1. The IMPAACT 2017 study (MOCHA study) was the first to use these injectable formulations in adolescents (aged 12-17 years) living with HIV-1. Herein, we report acceptability and tolerability outcomes in cohort 1 of the study.<h4>Methods</h4>In this a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study, with continuation of pre-study oral combination antiretroviral treatment (ART), 55 adolescents living with HIV-1 were enrolled to receive sequential doses of either long-acting cabotegravir or rilpivirine and 52 received at least two injections. Participants had a body weight greater than 35 kg and The lancet. HIVAcceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.PMC11061207UM1 AI068632UM1AI068616UM1 AI106716HHSN275201800001IUM1AI106716U01 AI069463HHSN275201800001CUM1 AI068616UM1AI068632UM1 AI069463U01 AI068632UM1 AI069399Zabih SNaidoo MHarrington CWhitson KCamacho-Gonzalez AHuang JBuisson SPaul MEWard SVan Solingen-Ristea RMCrauwels HIMPAACT 2017 TeamGaur AHAdeyeye ABest BMHanley SPatel FLowenthal EDAgwu ALCapparelli EVTownley EChounta VBearden ABolton-Moore CMcCoig CCMathiba SRSmith-Anderson CCalabrese KOunchanum PVandermeulen KKneebone JHeckman BD'Angelo JMilligan ROhrenschall RYin DEChapman JBaltrusaitis KIMPAACT 2017 CollaboratorsfalseAcceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.<h4>Background</h4>Long-acting injectable cabotegravir and rilpivirine have demonstrated safety, acceptability, and efficacy in adults living with HIV-1. The IMPAACT 2017 study (MOCHA study) was the first to use these injectable formulations in adolescents (aged 12-17 years) living with HIV-1. Herein, we report acceptability and tolerability outcomes in cohort 1 of the study.<h4>Methods</h4>In this a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study, with continuation of pre-study oral combination antiretroviral treatment (ART), 55 adolescents living with HIV-1 were enrolled to receive sequential doses of either long-acting cabotegravir or rilpivirine and 52 received at least two injections. Participants had a body weight greater than 35 kg and 2024-01-01T00:00:00Z2024 Apr2026-06-01T14:42:55.751Z2026-04-08T13:24:04.498ZS-EPMC110612073853816110.1016/s2352-3018(23)00301-610.1016/S2352-3018(23)00301-6